Welcome to the July issue of The Pipeline from Precision for Medicine, featuring video, articles, and on-demand content. You’ll find new technology for managing trial samples, insights from American Society of Gene & Cell Therapy (ASGCT)2021,best practices for expanding Phase 1/2 studies and more. We hope you’ll find this information valuable as you conquer the complexity inherent in R&D innovation.

The Pipeline features timely insights from our experts in the lab, clinical trials, and data science, designed to help innovative researchers unwind complexity. It is published by Precision for Medicine.

Deborah Phippard, PhD, Global Head of Research
Tobias Guennel, PhD, SVP, Product Development & Systems Integration
Tamiera Harris, PHD, MBA, Sr Dir, Operational Strategy

Phase 1/2 Combination Studies: Best Practices When Moving From Escalation to Expansion

Clinical study designs, specifically those that combine Phase 1 and Phase 2 trials, are becoming increasingly common as sponsors pursue more aggressive clinical development timelines. In this article, discover the best practices and elements to be aware of when managing a Phase 1/2 combination oncology study and how to effectively and efficiently move from escalation to expansion stages.

Accelerating Precision Oncology with a Novel NGS Screening Initiative

An ambitious next generation sequencing (NGS) initiative is screening thousands of biospecimens—both Formalin-Fixed Paraffin-Embedded (FFPE) and liquid biopsies—for key biomarkers across 11 cancer indications. The 2-part project, run by Precision for Medicine and multiple research partners, will turn these biospecimens into more powerful tools for cancer researchers. FIND OUT HOW TO ACQUIRE THESE BIOSPECIMENS >

Contact us and let us connect you with the right expert.